Background: We previously reported that loss of mutations ("regressive" mutational trajectories) from primary tumors to metastases associated with the oligo-metastatic status in colorectal cancer (CRC). The present study was undertaken in order to analyze the mutational trajectories of in a well-characterized cohort of CRC patients who developed poly- or oligo-metastatic disease.
Material And Methods: Patients were treated and followed-up according to European Society of Medical Oncology guidelines. Primary CRC FFPE tissue and metastatic circulating-free DNA were extracted using the QIAamp DNA specific kits (Qiagen, Hilden, Germany). Samples were sequenced with the Oncomine Solid Tumour DNA kit (Thermo Fisher Scientific, Waltham, MA, USA). Plasma collection for liquid biopsy was done from 1 to 14 days before starting first-line chemotherapy. Analysis of the prognostic power of evolutionary trajectories was done with uni- and multivariate analyses.
Results: One-hundred-fourteen patients were enrolled. Sixty-three patients presented with mutated (mut) and 51 with wild-type (wt). mutational concordance was high (70.1%).Two divergent subsets were identified: mut in primary tumors and wt in metastatic ones (regressive: mut → wt in 8.8% of patients), and (progressive: wtK → mut in 21.1% of patients). An association between regressive trajectory and the oligo-metastatic status (P <0.0001) was found. At multivariate analysis, regressive and progressive mutational trajectories emerged as independent prognostic factors for survival, with Hazard Ratios of 0.22 (CI 95%: 0.08-0.61; median survival: not reached) and 2.70 (CI 95%: 1.11-6.56, median survival: 12.1 months), respectively.
Conclusions: Our data provide evidence that the evolutionary trajectories of can have a strong clinical prognostic role and that they can be involved in discriminating between poly-metastatic aggressive oligo-metastatic indolent CRC.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039443 | PMC |
| http://dx.doi.org/10.3389/fonc.2021.632962 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparative efficacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world study.
BJC Rep
February 2024
Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel.
Article Synopsis
- The study compares the effectiveness and safety of combined CTLA-4 and PD-1 blockade therapy to anti-PD-1 monotherapy in treating metastatic melanoma patients.
- Results indicate no overall survival difference between the two treatments for the entire cohort, but combined therapy showed better results for patients with multi-organ metastasis, while monotherapy was more beneficial for those with oligo-organ metastasis.
- Patients receiving combination therapy also faced significantly higher hospitalization rates from adverse immune-related events when they had oligo-organ metastasis, highlighting the need for careful treatment selection.
Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study.
BJU Int
February 2025
St. Vincent's Prostate Cancer Research Centre, Sydney, New South Wales, Australia.
Objectives: To prospectively compare systemic anti-tumour immune responses induced by irreversible electroporation (IRE) and robot-assisted radical prostatectomy (RARP) in patients with localised intermediate-risk prostate cancer (PCa).
Patients And Methods: Between February 2021 and June 2022, before and after treatment (at 5, 14 and 30 days) peripheral blood samples of 30 patients with localised PCa were prospectively collected. Patient inclusion criteria were: International Society of Urological Pathologists Grade 2-3, clinical cancer stage ≤T2c, prostate-specific antigen level <20 ng/mL).
Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.
Theranostics
April 2024
Department of Radiation Oncology, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Hypofractionated radiotherapy (hRT) can induce a T cell-mediated abscopal effect on non-irradiated tumor lesions, especially in combination with immune checkpoint blockade (ICB). However, clinically, this effect is still rare, and ICB-mediated adverse events are common. Lenalidomide (lena) is an anti-angiogenic and immunomodulatory drug used in the treatment of hematologic malignancies.
View Article and Find Full Text PDFRadiotherapy for Lung Metastases: Conventional to Stereotactic Body Radiation Therapy.
Semin Radiat Oncol
April 2023
Department of Radiation Oncology, Princess Margaret Cancer Centre, University of Toronto, Toronto, Ontario, Canada.; Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada.. Electronic address:
The lung parenchyma and adjacent tissues are one of the most common sites of metastatic disease. Traditionally, the approach to treatment of a patient with lung metastases has been with systemic therapy, with radiotherapy being reserved for palliative management of symptomatic disease. The concept of oligo metastatic disease has paved the way for more radical treatment options, administered either alone or as local consolidative therapy in addition to systemic treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!